Age Adjusted Prostate Specific Antigen and Prostate Specific Antigen Velocity Cut Points in Prostate Cancer Screening

Journal of Urology

Volumn 177, Issue 2, 2007, Pages 499-504

  Moul, Judd W ^a   Sun, Leon ^a   Hotaling, James M ^a   Fitzsimons, Nicholas J ^a   Polascik, Thomas J ^a   Robertson, Cary N ^a   Dahm, Philipp ^a   Anscher, Mitchell S ^a   Mouraviev, Vladimir ^a   Pappas, Paul A ^a   Albala, David M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

age groups; differential threshold; predictive value of tests; prevalence; ROC curve

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANALYTICAL PARAMETERS; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; DATA BASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33846029534     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.09.063     Document Type: Article

References (20)

1. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. American Urological Association 1992 Policy Statement Book (1992), American Urological Association, Baltimore 4-20
2. Woolf S.H. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 333 (1995) 1401
3. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
4. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Growley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66
5. Carroll P.R. Editorial Comment. Urol Oncol 23 (2005) 459
6. Ashley T. Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. J Insur Med 37 (2005) 261
7. Zhu H., Roehl K.A., Antenor J.A., and Catalona W.J. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66 (2005) 547-551
8. Loeb S., Gonzalez C.M., Roehl K.A., Han M., Antenor J.A., Yap R.L., et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 175 (2006) 902
9. Loeb S., Roehl K.A., Antenor J.A., Catalona W.J., Suarez B.K., and Nadler R.B. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 (2006) 316
10. Nadler R.B., Loeb S., Roehl K.A., Antenor J.A., Eggener S., and Catalona W.J. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 174 (2005) 2154
11. Moul J.W. Screening for prostate cancer in military populations. Mil Med 170 (2005) 905
12. Datta M.W., Dhir R., Dobbin K., Bosland M.C., Melamed J., Becich M.J., et al. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource. J Urol 173 (2005) 1546
13. Kristal A.R., Chi C., Tangen C.M., Goodman P.J., Etzioni R., and Thompson I.M. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 106 (2006) 320
14. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
15. Catalona W.J., Partin A.W., Finlay J.A., Chan D.W., Rittenhouse H.G., Wolfert R.L., et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54 (1999) 220
16. Freedland S.J., Mangold L.A., Walsh P.C., and Partin A.W. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 174 (2005) 1276
17. Aleman M., Karakiewicz P.I., Kupelian P., Kattan M.W., Graefen M., Cagiannos I., et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 62 (2003) 70
18. Carter H.B. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. Urology 55 (2000) 796
19. Walsh P.C. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality. A case-control study. J Urol 174 (2005) 1824
20. Punglia R.S., D'Amico A.V., Catalona W.J., Roehl K.A., and Kuntz K.M. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer 106 (2006) 1507